These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 24911489)

  • 21. Rare-disease project has global ambitions.
    Abbott A
    Nature; 2011 Apr; 472(7341):17. PubMed ID: 21475168
    [No Abstract]   [Full Text] [Related]  

  • 22. Targeting shared molecular etiologies to accelerate drug development for rare diseases.
    Zanello G; Garrido-Estepa M; Crespo A; O'Connor D; Nabbout R; Waters C; Hall A; Taglialatela M; Chan CH; Pearce DA; Dooms M; Brooks PJ
    EMBO Mol Med; 2023 Jul; 15(7):e17159. PubMed ID: 37366158
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Metaplastic breast cancer: clinical overview and molecular aberrations for potential targeted therapy.
    Abouharb S; Moulder S
    Curr Oncol Rep; 2015 Mar; 17(3):431. PubMed ID: 25691085
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeted therapy: a potential oversight in trial protocol.
    Moorthy T
    Lancet Oncol; 2018 Sep; 19(9):e439. PubMed ID: 30191846
    [No Abstract]   [Full Text] [Related]  

  • 25. Innovative design and analysis for rare disease drug development.
    Chow SC; Huang Z
    J Biopharm Stat; 2020 May; 30(3):537-549. PubMed ID: 32065047
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ethical, legal and social implications of rare diseases and orphan drugs in Europe: meeting report of a Brocher symposium.
    Picavet E; Cassiman D; Pinxten W; Simoens S
    Expert Rev Pharmacoecon Outcomes Res; 2013 Oct; 13(5):571-3. PubMed ID: 24138643
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Which efficacy trials for drugs for rare diseases?].
    Traversa G; Trotta F
    Epidemiol Prev; 2017; 41(5-6):318-319. PubMed ID: 29119773
    [No Abstract]   [Full Text] [Related]  

  • 28. A checklist for clinical trials in rare disease: obstacles and anticipatory actions-lessons learned from the FOR-DMD trial.
    Crow RA; Hart KA; McDermott MP; Tawil R; Martens WB; Herr BE; McColl E; Wilkinson J; Kirschner J; King WM; Eagle M; Brown MW; Hirtz D; Lochmuller H; Straub V; Ciafaloni E; Shieh PB; Spinty S; Childs AM; Manzur AY; Morandi L; Butterfield RJ; Horrocks I; Roper H; Flanigan KM; Kuntz NL; Mah JK; Morrison L; Darras BT; von der Hagen M; Schara U; Wilichowski E; Mongini T; McDonald CM; Vita G; Barohn RJ; Finkel RS; Wicklund M; McMillan HJ; Hughes I; Pegoraro E; Bryan Burnette W; Howard JF; Thangarajh M; Campbell C; Griggs RC; Bushby K; Guglieri M
    Trials; 2018 May; 19(1):291. PubMed ID: 29793540
    [TBL] [Abstract][Full Text] [Related]  

  • 29. First CD123-targeted drug approved after wowing in rare cancer.
    Dolgin E
    Nat Biotechnol; 2019 Mar; 37(3):202-203. PubMed ID: 30833771
    [No Abstract]   [Full Text] [Related]  

  • 30. Targeted Therapies in Older Adults With Breast Cancer: What Do We Know?
    Strulov Shachar S; Hurria A; Muss HB
    J Clin Oncol; 2016 Oct; 34(28):3486-8. PubMed ID: 27432932
    [No Abstract]   [Full Text] [Related]  

  • 31. Targeted therapy in rare cancers--adopting the orphans.
    Munoz J; Kurzrock R
    Nat Rev Clin Oncol; 2012 Nov; 9(11):631-42. PubMed ID: 22965154
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Unveiling the molecular pathogenesis of chordoma: a new paradigm for molecular targeting of rare cancers.
    Dei Tos AP
    J Pathol; 2011 Apr; 223(5):565-6. PubMed ID: 21394718
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Improved strategies for designing lupus trials with targeted therapies: learning from 65 years of experience.
    Wallace DJ
    Lupus; 2016 Sep; 25(10):1141-9. PubMed ID: 27497258
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tackling rare diseases: Clinical trials on chips.
    Blumenrath SH; Lee BY; Low L; Prithviraj R; Tagle D
    Exp Biol Med (Maywood); 2020 Jul; 245(13):1155-1162. PubMed ID: 32397761
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Modifying protein misfolding.
    Jones D
    Nat Rev Drug Discov; 2010 Nov; 9(11):825-7. PubMed ID: 21030987
    [No Abstract]   [Full Text] [Related]  

  • 36. The FDA Breakthrough-Drug Designation - Four Years of Experience.
    Darrow JJ; Avorn J; Kesselheim AS
    N Engl J Med; 2018 Apr; 378(15):1444-1453. PubMed ID: 29641970
    [No Abstract]   [Full Text] [Related]  

  • 37. Novel medical therapeutics in glioblastomas, including targeted molecular therapies, current and future clinical trials.
    Quant EC; Wen PY
    Neuroimaging Clin N Am; 2010 Aug; 20(3):425-48. PubMed ID: 20708556
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Case studies in rare disease small molecule discovery and development.
    Schmidt D; Thompson C
    Bioorg Med Chem Lett; 2020 Nov; 30(21):127462. PubMed ID: 32791196
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Characteristics and Public Availability of Results of Clinical Trials on Rare Diseases Registered at Clinicaltrials.gov.
    Dechartres A; Riveros C; Harroch M; Faber T; Ravaud P
    JAMA Intern Med; 2016 Apr; 176(4):556-8. PubMed ID: 26954340
    [No Abstract]   [Full Text] [Related]  

  • 40. MASTER KEY Project: Powering Clinical Development for Rare Cancers Through a Platform Trial.
    Okuma HS; Yonemori K; Narita SN; Sukigara T; Hirakawa A; Shimizu T; Shibata T; Kawai A; Yamamoto N; Nakamura K; Nishida T; Fujiwara Y
    Clin Pharmacol Ther; 2020 Sep; 108(3):596-605. PubMed ID: 32112563
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.